Figure 2.

The antiviral potency of the oligonucleotides is dependent on both the presence of a functional 2–5A group and the sequence of the antisense cassette. Oligonucleotides were added twice to RSV-infected cells at 3.3 μM per dose as described. The horizontal bars show the average reduction in infectious RSV yields as determined by viral plaque assays. The standard errors are indicated by the vertical lines connected to the bars. The numbers shown in parenthesis within the bars are the numbers of experiments used to obtain the data. The percent reduction in virus yield is defined as [1−(the number of viral plaques obtained from the oligonucleotide-treated cells/the number of viral plaques obtained from the untreated cells) × 100]. (Left) The oligonucleotides used. (Right) The predicted structures of the RNA targets and the oligonucleotide binding sites (bold lines) correspond to those shown in Fig. 1.